Viewing Company
Company Name:
Acurx Pharmaceuticals, Inc.
CIK:
1736243
Phone:
None
Fiscal Year End:
None
Entity Type:
SIC:
-
Category Type:
Entity Name:
None
First Filing Date:
2021-08-13
Last Filing Date:
2025-05-12
SEC Filings
| Start | End | Frame | Filed | ACCN | Value | View |
|---|---|---|---|---|---|---|
| 2021-04-01 | 2021-06-30 | CY2021Q2 | 2021-08-13 | 0001104659-21-105074 | $ 6,968,341 | View |
| 2021-07-01 | 2021-09-30 | CY2020Q3 | 2021-11-12 | 0001104659-21-138038 | $ 10,116,403 | View |
| 2021-01-01 | 2021-12-31 | CY2021Q4I | 2022-03-16 | 0001410578-22-000399 | $ 6,100,000 | View |
| 2022-01-01 | 2022-03-31 | CY2021Q1 | 2022-05-10 | 0001410578-22-001250 | $ -1,876,000 | View |
| 2022-01-01 | 2022-06-30 | CY2022Q2I | 2022-08-12 | 0001410578-22-002396 | $ 50,247 | View |
| 2022-01-01 | 2022-09-30 | CY2021Q3I | 2022-11-10 | 0001558370-22-017408 | $ 9,763,068 | View |
| 2023-01-01 | 2023-03-31 | CY2023Q1I | 2023-05-12 | 0001558370-23-009495 | $ 6 | View |
| 2022-01-01 | 2022-12-31 | CY2022Q4I | 2023-03-15 | 0001558370-23-003929 | $ 0 | View |
| 2025-01-01 | 2025-03-31 | CY2025Q1I | 2025-05-12 | 0001558370-25-007371 | $ 3,394 | View |
| 2023-01-01 | 2023-05-18 | CY2021Q2I | 2023-08-11 | 0001558370-23-014645 | $ 4,000,000 | View |
| 2023-01-01 | 2022-07-25 | CY2021Q2I | 2023-11-13 | 0001558370-23-018824 | $ 171,409 | View |
| 2023-01-01 | 2023-12-31 | CY2023Q4I | 2024-03-15 | 0001558370-24-003401 | $ 55,342,000 | View |
| 2024-01-01 | 2024-03-31 | CY2024Q1 | 2024-05-14 | 0001558370-24-008130 | $ 894,523 | View |
| 2024-04-01 | 2024-06-30 | CY2024Q2I | 2024-08-08 | 0001558370-24-011587 | $ 1,016,998 | View |
| 2024-07-01 | 2024-09-30 | CY2024Q3I | 2024-11-12 | 0001558370-24-015310 | $ 51,127 | View |
| 2024-01-01 | 2024-12-31 | CY2024 | 2025-03-17 | 0001558370-25-003117 | $ 1 | View |
SEC Facts By Type
| Type | Name | Description | View |
|---|---|---|---|
| dei | Entity Public Float | The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter. | View |
| us-gaap | Additional Paid in Capital | Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock. | View |
| us-gaap | Earnings Per Share, Basic and Diluted | The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. | View |
| us-gaap | Research and Development Expense | The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. | View |
| us-gaap | Retained Earnings (Accumulated Deficit) | The cumulative amount of the reporting entity's undistributed earnings or deficit. | View |
| us-gaap | Weighted Average Number of Shares Outstanding, Basic | Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. | View |
| us-gaap | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. | View |
| us-gaap | Proceeds from Issuance of Common Stock | The cash inflow from the additional capital contribution to the entity. | View |
| us-gaap | Proceeds from Issuance of Warrants | The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). | View |
| us-gaap | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate | The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. | View |
| us-gaap | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value | Weighted average grant-date fair value of options vested. | View |
| us-gaap | Stockholders' Equity Attributable to Parent | Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. | View |
| us-gaap | Number of Operating Segments | Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. | View |
| us-gaap | Other Accounts Payable and Accrued Liabilities | Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer. | View |
| dei | Entity Common Stock, Shares Outstanding | Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. | View |
| us-gaap | Weighted Average Number of Shares Outstanding, Basic and Diluted | Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS). | View |
| us-gaap | Accounts Payable and Accrued Liabilities, Current | Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits. | View |
| us-gaap | Accounts Payable and Other Accrued Liabilities, Current | Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer. | View |
| us-gaap | Accrued Professional Fees, Current | Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). | View |
| us-gaap | Share-based Payment Arrangement, Expense | Amount of expense for award under share-based payment arrangement. Excludes amount capitalized. | View |
| us-gaap | Assets | Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. | View |
| us-gaap | Cash | Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation. | View |
| us-gaap | Cash and Cash Equivalents, at Carrying Value | Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. | View |
| us-gaap | Cash and Cash Equivalents, Period Increase (Decrease) | Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes. | View |
| us-gaap | Cash, FDIC Insured Amount | The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation. | View |
| us-gaap | Common Stock, Capital Shares Reserved for Future Issuance | Aggregate number of common shares reserved for future issuance. | View |
| us-gaap | Common Stock, Par or Stated Value Per Share | Face amount or stated value per share of common stock. | View |
| us-gaap | Common Stock, Shares Authorized | The maximum number of common shares permitted to be issued by an entity's charter and bylaws. | View |
| us-gaap | Common Stock, Shares, Issued | Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. | View |
| us-gaap | Common Stock, Shares, Outstanding | Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. | View |
| us-gaap | Common Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. | View |
| us-gaap | Current Federal, State and Local, Tax Expense (Benefit) | Amount of current state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations. | View |
| us-gaap | Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount | Amount of commitment made to pay deferred cash remuneration. | View |
| us-gaap | Deferred Compensation Share-based Arrangements, Liability, Current | Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable within one year (or the operating cycle, if longer). | View |
| us-gaap | Earnings Per Share, Basic | The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. | View |
| us-gaap | Earnings Per Share, Diluted | The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. | View |
| us-gaap | Effective Income Tax Rate Reconciliation, Percent | Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. | View |
| us-gaap | Employee-related Liabilities, Current | Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). | View |
| us-gaap | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | Amount of cost to be recognized for option under share-based payment arrangement. | View |
| us-gaap | General and Administrative Expense | The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. | View |
| us-gaap | Income Tax Expense (Benefit) | Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. | View |
| us-gaap | Increase (Decrease) in Accounts Payable and Accrued Liabilities | The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. | View |
| us-gaap | Increase (Decrease) in Prepaid Expense | The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods. | View |
| us-gaap | Issuance of Stock and Warrants for Services or Claims | Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims. | View |
| us-gaap | Liabilities | Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. | View |
| us-gaap | Liabilities and Equity | Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. | View |
| us-gaap | Liabilities, Current | Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. | View |
| us-gaap | Net Cash Provided by (Used in) Financing Activities | Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. | View |
| us-gaap | Net Cash Provided by (Used in) Operating Activities | Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. | View |
| us-gaap | Net Income (Loss) Attributable to Parent | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. | View |
| us-gaap | Operating Expenses | Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. | View |
| us-gaap | Payments of Stock Issuance Costs | The cash outflow for cost incurred directly with the issuance of an equity security. | View |
| us-gaap | Prepaid Expense, Current | Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. | View |
| us-gaap | Proceeds from Issuance Initial Public Offering | The cash inflow associated with the amount received from entity's first offering of stock to the public. | View |
| us-gaap | Proceeds from Issuance of Private Placement | The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. | View |
| us-gaap | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. | View |
| us-gaap | Related Party Transaction, Expenses from Transactions with Related Party | Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party. | View |
| us-gaap | Selling, General and Administrative Expense | The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. | View |
| us-gaap | Share-based Payment Arrangement, Noncash Expense | Amount of noncash expense for share-based payment arrangement. | View |
| us-gaap | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value | The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). | View |
| us-gaap | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | The risk-free interest rate assumption that is used in valuing an option on its own shares. | View |
| us-gaap | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate | Rate of weighted-average expected volatility for award under share-based payment arrangement. | View |
| us-gaap | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | Gross number of share options (or share units) granted during the period. | View |
| us-gaap | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. | View |
| us-gaap | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. | View |
| us-gaap | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | Number of options outstanding, including both vested and non-vested options. | View |
| us-gaap | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. | View |
| us-gaap | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options. | View |
| us-gaap | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares | Number of options vested. | View |
| us-gaap | Shares Issued, Price Per Share | Per share or per unit amount of equity securities issued. | View |
| us-gaap | Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture | Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). | View |
| us-gaap | Stockholders' Equity Note, Stock Split, Conversion Ratio | Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. | View |
| us-gaap | Stock Issued During Period, Shares, Conversion of Units | The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit). | View |
| us-gaap | Stock Issued During Period, Shares, New Issues | Number of new stock issued during the period. | View |
| us-gaap | Stock Issued During Period, Value, Conversion of Units | Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit). | View |
| us-gaap | Stock Issued During Period, Value, Issued for Services | Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders. | View |
| us-gaap | Stock Issued During Period, Value, New Issues | Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. | View |
| us-gaap | Weighted Average Number of Shares Outstanding, Diluted | The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. | View |
| us-gaap | Deferred Tax Assets, Gross | Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards. | View |
| us-gaap | Deferred Tax Assets, in Process Research and Development | Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination. | View |
| us-gaap | Deferred Tax Assets, Operating Loss Carryforwards | Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards. | View |
| us-gaap | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation. | View |
| us-gaap | Deferred Tax Assets, Valuation Allowance | Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized. | View |
| us-gaap | Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | Percentage of domestic federal statutory tax rate applicable to pretax income (loss). | View |
| us-gaap | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent | Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets. | View |
| us-gaap | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent | Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense. | View |
| us-gaap | Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent | Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit). | View |
| us-gaap | Operating Loss Carryforwards | Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws. | View |
| us-gaap | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. | View |
| us-gaap | Assets, Current | Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. | View |
| us-gaap | Deferred Costs, Noncurrent | Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent. | View |
| us-gaap | Increase (Decrease) in Deferred Charges | The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation. | View |
| us-gaap | Class of Warrant or Right, Outstanding | Number of warrants or rights outstanding. | View |
| us-gaap | Gain (Loss) on Extinguishment of Debt | Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. | View |
| us-gaap | Income Taxes Receivable, Current | Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. | View |
| us-gaap | Class of Warrant or Right, Exercise Price of Warrants or Rights | Exercise price per share or per unit of warrants or rights outstanding. | View |
| us-gaap | Class of Warrant or Right, Number of Securities Called by Warrants or Rights | Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. | View |
| us-gaap | Deferred Tax Assets, Tax Credit Carryforwards, Research | Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards. | View |
| us-gaap | Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent | Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments. | View |
| us-gaap | Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired | The fair value of capitalized costs of a research and development nature that were acquired during the period in a transaction other than a business combination. | View |
| us-gaap | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. | View |
| us-gaap | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. | View |
| us-gaap | Tax Credit Carryforward, Amount | The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws. | View |
| us-gaap | Unrecognized Tax Benefits | Amount of unrecognized tax benefits. | View |
| us-gaap | Sale of Stock, Consideration Received on Transaction | Cash received on stock transaction after deduction of issuance costs. | View |
| us-gaap | Conversion of Stock, Shares Converted | "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. ""Part noncash"" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." | View |
| us-gaap | Fair Value Adjustment of Warrants | Amount of expense (income) related to adjustment to fair value of warrant liability. | View |
| us-gaap | 3588549 | None | View |
| us-gaap | Warrants Not Settleable in Cash, Fair Value Disclosure | Fair value portion of warrants not settleable in cash classified as equity. | View |
| us-gaap | Accounts and Other Receivables, Net, Current | Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer. | View |
| us-gaap | Deferred Tax Assets, Other | Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other. | View |
| us-gaap | Increase (Decrease) in Accounts and Other Receivables | The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables. | View |
| us-gaap | Proceeds from Warrant Exercises | The cash inflow associated with the amount received from holders exercising their stock warrants. | View |
| us-gaap | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value | Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. | View |
| us-gaap | APIC, Share-based Payment Arrangement, Increase for Cost Recognition | Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. | View |
Chart of Accounts => Accounts
| Name | View |
|---|---|
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | View |
| Related Party Transaction, Expenses from Transactions with Related Party | View |
| Research and Development Expense | View |
| Retained Earnings (Accumulated Deficit) | View |
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | View |
| Class of Warrant or Right, Outstanding | View |
| Gain (Loss) on Extinguishment of Debt | View |
| Proceeds from Issuance of Common Stock | View |
| Proceeds from Issuance of Warrants | View |
| Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate | View |
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value | View |
| Stockholders' Equity Attributable to Parent | View |
| Number of Operating Segments | View |
| Other Accounts Payable and Accrued Liabilities | View |
| Accounts Payable and Accrued Liabilities, Current | View |
| Accounts Payable and Other Accrued Liabilities, Current | View |
| Accrued Professional Fees, Current | View |
| Additional Paid in Capital | View |
| Share-based Payment Arrangement, Expense | View |
| Assets | View |
| Cash | View |
| Cash and Cash Equivalents, at Carrying Value | View |
| Cash and Cash Equivalents, Period Increase (Decrease) | View |
| Cash, FDIC Insured Amount | View |
| Common Stock, Capital Shares Reserved for Future Issuance | View |
| Common Stock, Par or Stated Value Per Share | View |
| Common Stock, Shares Authorized | View |
| Common Stock, Shares, Issued | View |
| Common Stock, Shares, Outstanding | View |
| Common Stock, Value, Issued | View |
| Current Federal, State and Local, Tax Expense (Benefit) | View |
| Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount | View |
| Deferred Compensation Share-based Arrangements, Liability, Current | View |
| Earnings Per Share, Basic | View |
| Earnings Per Share, Basic and Diluted | View |
| Earnings Per Share, Diluted | View |
| Effective Income Tax Rate Reconciliation, Percent | View |
| Employee-related Liabilities, Current | View |
| Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | View |
| General and Administrative Expense | View |
| Income Tax Expense (Benefit) | View |
| Increase (Decrease) in Accounts Payable and Accrued Liabilities | View |
| Increase (Decrease) in Prepaid Expense | View |
| Issuance of Stock and Warrants for Services or Claims | View |
| Liabilities | View |
| Liabilities and Equity | View |
| Liabilities, Current | View |
| Net Cash Provided by (Used in) Financing Activities | View |
| Net Cash Provided by (Used in) Operating Activities | View |
| Net Income (Loss) Attributable to Parent | View |
| Operating Expenses | View |
| Payments of Stock Issuance Costs | View |
| Prepaid Expense, Current | View |
| Proceeds from Issuance Initial Public Offering | View |
| Proceeds from Issuance of Private Placement | View |
| Selling, General and Administrative Expense | View |
| Share-based Payment Arrangement, Noncash Expense | View |
| Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value | View |
| Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | View |
| Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate | View |
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | View |
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | View |
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | View |
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | View |
| Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | View |
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares | View |
| Shares Issued, Price Per Share | View |
| Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture | View |
| Stockholders' Equity Note, Stock Split, Conversion Ratio | View |
| Stock Issued During Period, Shares, Conversion of Units | View |
| Stock Issued During Period, Shares, New Issues | View |
| Stock Issued During Period, Value, Conversion of Units | View |
| Stock Issued During Period, Value, Issued for Services | View |
| Stock Issued During Period, Value, New Issues | View |
| Weighted Average Number of Shares Outstanding, Diluted | View |
| Weighted Average Number of Shares Outstanding, Basic and Diluted | View |
| Weighted Average Number of Shares Outstanding, Basic | View |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | View |
| Deferred Tax Assets, Gross | View |
| Deferred Tax Assets, in Process Research and Development | View |
| Deferred Tax Assets, Operating Loss Carryforwards | View |
| Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | View |
| Deferred Tax Assets, Valuation Allowance | View |
| Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | View |
| Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent | View |
| Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent | View |
| Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent | View |
| Operating Loss Carryforwards | View |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | View |
| Assets, Current | View |
| Deferred Costs, Noncurrent | View |
| Increase (Decrease) in Deferred Charges | View |
| Class of Warrant or Right, Exercise Price of Warrants or Rights | View |
| Class of Warrant or Right, Number of Securities Called by Warrants or Rights | View |
| Deferred Tax Assets, Tax Credit Carryforwards, Research | View |
| Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent | View |
| Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired | View |
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | View |
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | View |
| Tax Credit Carryforward, Amount | View |
| Unrecognized Tax Benefits | View |
| Sale of Stock, Consideration Received on Transaction | View |
| Conversion of Stock, Shares Converted | View |
| Fair Value Adjustment of Warrants | View |
| 3557386 | View |
| Warrants Not Settleable in Cash, Fair Value Disclosure | View |
| Accounts and Other Receivables, Net, Current | View |
| Deferred Tax Assets, Other | View |
| Increase (Decrease) in Accounts and Other Receivables | View |
| Proceeds from Warrant Exercises | View |
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value | View |
| APIC, Share-based Payment Arrangement, Increase for Cost Recognition | View |
| Income Taxes Receivable, Current | View |